SYN-Tech Chem & Pharm Co Ltd

SYN-Tech Chem & Pharm Co Ltd maintains a strong liquidity position, with a current ratio of 2.69 and cash and equivalents amounting to TWD 403.07 million, which represents 14.2% of total assets. The company's debt-to-equity ratio is 0.1, indicating a conservative capital structure with minimal reliance on debt financing. Free cash flow of TWD 82.88 million suggests the company generates sufficient cash to support operations and potentially fund growth initiatives.

Profitability metrics show a return on equity (ROE) of 3.89% and a return on assets (ROA) of 3.08%, which are below the industry median for pharmaceutical companies. The net profit margin is 32.4%, calculated from a net income of TWD 87.38 million on revenue of TWD 269.78 million. These figures suggest that while the company is profitable, it may not be outperforming its peers in terms of asset and equity utilization.

The company's revenue is concentrated in a single business segment, as disclosed in its latest financial report, with no geographic breakdown provided. This lack of diversification may expose the company to higher operational and market risks if demand in its primary market fluctuates.

Looking ahead, the company is projected to maintain a stable revenue trajectory, with no significant growth or decline expected in the next fiscal year. Capital expenditures are negative at TWD -39.24 million, indicating asset disposals or reduced investment in physical infrastructure. This may reflect a strategic shift toward cost optimization or a focus on intangible assets such as R&D.

Risk factors include low liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash reserves mitigate credit risk, but its profitability metrics suggest room for improvement in operational efficiency. No dilution is expected in the near term, as shares outstanding remain unchanged between basic and diluted measures.

Recent filings and transcripts do not indicate any material events or strategic shifts. The company appears to be operating within a stable financial and regulatory environment, with no disclosed regulatory or compliance issues in the latest reports.

Revenue grew at a 9.8% CAGR over four years, showing consistent top-line expansion.

Low debt-to-equity ratio of 0.10 suggests a conservative capital structure with minimal leverage risk.

Return on equity of 3.9% remains above the pharmaceutical cohort median of 2.9%.

Cash conversion ratio of 0.70 falls below the cohort median of 0.95, indicating poor cash generation.

Capital expenditure intensity is in the bottom quartile, potentially limiting future growth investments.

Revenue TWD 1.11B, +13,0% YoY; Operating income +21,4% YoY.

• ▍Revenue TWD 1.11B, +13,0% YoY
• ▍Operating income +21,4% YoY
• ▍Net income −15,0% YoY
• ▍Free cash flow −11,2% YoY
• ▍Net margin 22.5%

Revenue TWD 986.3M, +10,4% YoY; Operating income +437,3% YoY.

• ▍Revenue TWD 986.3M, +10,4% YoY
• ▍Operating income +437,3% YoY
• ▍Net income +66,7% YoY
• ▍Free cash flow −675,6% YoY
• ▍Net margin 29.9%

Revenue TWD 893.2M; Operating income -TWD 68.8M.

• ▍Revenue TWD 893.2M
• ▍Operating income -TWD 68.8M
• ▍Net margin 19.8%